Opendata, web and dolomites

RheoCare SIGNED

Rheological Monitoring of Chronic Respiratory Diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RheoCare project word cloud

Explore the words cloud of the RheoCare project. It provides you a very rough idea of what is the project "RheoCare" about.

protocols    software    5b    techniques    trials    phases    structures    plug    assesses    robustness    biomarkers    samples    technique    lung    2020    clinical    performance    protected    monitoring    specificity    commercialised    rheonova    efficiency    block    remoulding    airways    24k    feasibility    emergency    g8    plan    cf    supporting    building    secretions    manipulation    automated    diseases    causing    minutes    mortality    patent    ambition    china    attractive    patient    strategy    favouring    periodic    irreversible    reproducibility    segment    mucus    point    demonstrated    healthcare    spectrum    quantitative    treatment    capacity    rheocare    first    market    complete    medical    choose    develops    quantitatively    machine       priced    antibioresistances    accompanied    exacerbation    fibrosis    treatments    regarding    ip    rheology    lower    cystic    respiratory    crises    worldwide    assessing    exist    play    pulmonary    group    consumables    eight    rheometer    patients    benefit    biomarker    forecast    care    hospitalisations    attractively    crisis    80    commercialisation    predicting    device    acute    chronic    infections    personalised   

Project "RheoCare" data sheet

The following table provides information about the project.

Coordinator
RHEONOVA SAS 

Organization address
address: 31 BOULEVARD AGUTTE SEMBAT
city: GRENOBLE
postcode: 38000
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RHEONOVA SAS FR (GRENOBLE) coordinator 50˙000.00

Map

 Project objective

Chronic respiratory diseases are expected to become the third cause of mortality worldwide by 2020. Patients experience periodic acute exacerbation phases favouring infections of the lower airways and causing irreversible loss of pulmonary capacity. These crises cannot be forecast with current techniques and require emergency hospitalisations, leading to healthcare costs (€24k per crisis) and antibioresistances due to wide-spectrum treatments. Among respiratory diseases, we choose to target cystic fibrosis (CF) in Europe as organised care structures pre-exist. CF also represents a very attractive market segment of $4.5B across the Group of Eight (G8). Rheonova develops a unique monitoring test based on the rheology of lung secretions (mucus). The RheoCare project will provide a dedicated plug-and-play rheometer, with a quantitative biomarker and a specificity above 80%, allowing a point-of-care CF monitoring test within 10 minutes as a first step towards personalised healthcare. Our four-patent-protected technique already assesses treatments efficiency and is commercialised to researchers. Phase 1 clinical trials have demonstrated the reproducibility and the robustness of our biomarkers. Two new clinical protocols (Phase 2) proceed in order to demonstrate the medical benefit for the patient, i.e. the reduction of hospitalisations by predicting the exacerbation phases and assessing treatment performance quantitatively. Within three years, Phase 3 clinical trials will support the commercialisation of the device in EU and China. We will address the medical market with an attractively-priced machine accompanied with specific consumables needed to test mucus samples. To support our ambition, we need to implement an automated sample manipulation device. Three priority tasks remain to complete the feasibility study: (i) remoulding the software, (ii) supporting our commercialisation plan, and (iii) defining the IP strategy regarding this new building block.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RHEOCARE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RHEOCARE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

Woodywood pickering (2019)

Bio-based (fully renewable) cost effective Polymer for new generation of ecological Coatings leveraging a disruptive innovation in the use of Pickering emulsion.

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More